
AAPG Stock Forecast & Price Target
AAPG Analyst Ratings
Bulls say
Ascentage Pharma Group has exhibited strong commercial viability, with olverembatinib generating RMB 217.4 million (approximately US$30.3 million) in sales during the first half of 2025, marking a significant 93% year-over-year increase. The company's expansion in formulary coverage to over 295 hospitals, along with a 17% increase in DTP pharmacies and hospitals onboarded, highlights its growing market presence and accessibility for its innovative therapies. Furthermore, the favorable environment for mid-cap biotech firms, evidenced by a 58% year-to-date gain in a China Biotech ETF, underscores the optimistic investor sentiment towards the sector, positioning Ascentage Pharma favorably within this landscape.
Bears say
Ascentage Pharma Group faces multiple challenges that contribute to a negative outlook, primarily due to the ongoing volume-based procurement program which, although initially targeting generics, is creating downward pressure on margins and may hinder revenue growth for innovative therapies. Additionally, the company has experienced setbacks in clinical trials, notably the failure to meet primary endpoints, which diminishes its global expansion potential and could harm its competitive positioning in the market. Furthermore, slower adoption of its therapy Olverembatinib in China, coupled with the limitations in differentiating its products from established competitors, raises further concerns about the company’s future revenue prospects and overall financial stability.
This aggregate rating is based on analysts' research of Ascentage Pharma Group International and is not a guaranteed prediction by Public.com or investment advice.
AAPG Analyst Forecast & Price Prediction
Start investing in AAPG
Order type
Buy in
Order amount
Est. shares
0 shares